ENOV (Enovis) Short-Term Debt: $35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENOV Enovis Corp ENOV
64 GF Score
Price $26.94
GF Value $50.18
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Enovis Short-Term Debt?

Enovis ENOV +5.28% 64 Short-Term Debt is $35 Mil as of Mar. 2026. GuruFocus rates ENOV with a GF Score™ of 64/100 and a GF Value™ of $50.18 (Possible Value Trap). The stock has 6 warning signs investors should review.

Enovis's Short-Term Debt for the quarter that ended in Mar. 2026 was $35 Mil.

Enovis's quarterly Short-Term Debt increased from Sep. 2025 ($20 Mil) to Dec. 2025 ($35 Mil) but then stayed the same from Dec. 2025 ($35 Mil) to Mar. 2026 ($35 Mil).

Enovis's annual Short-Term Debt increased from Dec. 2023 ($0 Mil) to Dec. 2024 ($20 Mil) and increased from Dec. 2024 ($20 Mil) to Dec. 2025 ($35 Mil).

Enovis Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Enovis Short-Term Debt Related Terms

Enovis Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Enovis's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis Short-Term Debt Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.70 219.28 0.00 20.03 35.00

Enovis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.03 20.03 20.00 35.00 35.00
ENOV
64GF Score
Enovis Corp ENOV
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $35 Mil mean?
Enovis (ENOV) has a Short-Term Debt of $35 Mil as of Mar. 2026.
Is Enovis' Short-Term Debt too high?
Enovis' current Short-Term Debt is $35 Mil. Overall, Enovis has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' Short-Term Debt compare to INSP and PRCT?
Enovis' Short-Term Debt of $35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Enovis's current Short-Term Debt is $35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $50.18, compared to a current price of $26.94 — trading 46.3% below its estimated fair value. The current Short-Term Debt is $35 Mil. Enovis' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Enovis (ENOV), the current Short-Term Debt is $35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (ENOV) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of $26.94 is trading 46.3% below its estimated GF Value™ of $50.18. GuruFocus considers Enovis to be Possible Value Trap.

Key valuation signals for ENOV:

  • Short-Term Debt: $35 Mil
  • GF Value™: $50.18 vs. price of $26.94 (46.3% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
64GF Score

Get the complete analysis for ENOV

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.94
Price
$50.18
GF Value